outperform price
thesi updat ilmn earn becom volatil event
recent qsin context headlin revenu beat provid
sigh relief highlight america come back
strong china deceler moder said
revenu beat mainli driven collabor
revenu within servic mainli friendli
german neighbor given chang
annual revenue guid revenue growth implic
core instrument consum run tad
prior expect off-set collabor rev
hand could realiz collabor rev
would make impli guid revenue growth
conserv suspect debat tomorrow
st tri decid whether underli fundament
improv slippag pop-seq project
custom upgrad nextseq caus paus
valid new system scale ultim
near-term issu solv
larg scale pop seq project come on-line holder take
comfort fact earli stage
project thesi win longer term
given view reiter outperform rate
lower pt tad revenue estimate tad
consum smaller tp
pleas see guidanc color market color
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
sequenc consum moder low-teen vs mid-teen prior guidanc issu
driven lower pull-through low-throughput instrument custom transit
confid abil place nova meet fy guid
nh us contributor year
rais gm expect vs slightli guidanc issu bp
uk biobank expect revenu driver
emphasi system upgrad posit long-term signal demand drive util pull-
despit near-term pressur
china overal flat normal tariff stock last yr
strong growth clinic reproduct health oncolog w/ nipt double-digit
off-set research weak
data show broad research fund china y/i
america overal w/ mm hw array off-set sequenc strength grow clinic
europ driven larg scale initi hand novaseq placement emerg mkt
apac driven japan management note growth clinic research
genom inform demand grow nipt adopt broaden reimburs improv
live cover simpl oncolog includ liquid biopsi
overal dtc prob go return growth near-term
novaseq pull-through mm/yr
nextseq pull-through low end rang larg custom upgrad
miseq pull-through came rang larg number custom upgrad
 low end histor rang due multi-unit shipment associ uk
roughli hiseq cust convert novaseq
repres highest shipment quarter ever novaseq nextseq
uk biobank total project size rel clear focu cadenc ramp
full ramp start end see full impact gener momentum
us impact hope get ground earli next yr w/ infrastructur set go
nh impact though management state confid get start
overal work activ engag move quickli lower price point
depend scale
move forward management note transpar specif project contribut
collabor qgen/adaptive/oth clinic test incl ngs-base ivd test
ivd licens agreement strong contributor ad mm w/ margin drop-through
account beat
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin octob
analyst luke sergott vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
